### TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 082696 AND 091396—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
S.A. Louis Dreyfus et Cie, Winter Garden Citrus Products Cooperative, Winter Garden Citrus Products Cooperative	96–2806	09/09/96
Strata Holdings L.P., Scesaplana Settlement (a Liechtenstein trust), E&S Holdings Corporation	96-2802	09/10/96
Strata Holdings L.P., Ricardo Cisneros, E&S Holdings Corporation	96-2803	09/10/96
Apollo Real Estate Investment Fund II, L.P., Hollyrock, Ltd., Allright Corporation	96-2804	09/10/96
Mr. Yasuhiro Ohshima, Ricoh Company, Ltd., Vivitar Holding, Inc	96-2805	09/10/96
AEW Partners, L.P., Hollyrock, Ltd., Alfright Corporation	96-2807	09/10/96
Stimson Lumber Company, Plum Creek Timber Company, L.P., Plum Creek Timber Company, L.P	96-2808	09/10/96
The Prudential Insurance Company of America, Seagull Energy Corporation, Seagull Energy Corporation	96-2809	09/10/96
Seagull Energy Corporation, Global Natural Resources Inc., Global Natural Resources Inc.	96–2812	09/10/96
U.S. Office Products Company, James E. Claypoole, Bay State Computer Group, Inc	96–2813	09/10/96
James E. Claypoole, U.S. Office Products Company, U.S. Office Products Company	96–2814	09/10/96
E.J. Elliott, Ingersoll-Rand Company, California Pellet Mill Co & Silver Engineering Works Inc	96–2825	09/10/96
SunGard Data Systems Inc. CheckFree Corporation, CheckFree Securities Products Business	96–2827	09/10/96
Monsanto Company, Calgene, Inc., Calgene, Inc.	96–2828	09/10/96
AMF Holdings Inc., Charan Industries, Inc., Charan Industries, Inc.	96–2833	09/10/96
Sanford N. Penseler, Equity Holdings Limited, Denman Tire Corporation	96–2837	09/10/96
Hicks, Muse, Tate & Furst Equity Fund II, L.P., Sunrise Medical Inc., Comfort Clinic	96–2838	09/10/96
JP Foodservice, Inc., Charles A. Squeri, Squeri Food Service, Inc.	96–2842	09/10/96
Charles A. Squeri, JP Foodservice, Inc., JP Foodservice, Inc.	96–2843	09/10/96
The SK Equity Fund, L.P., Lawrence Merchandising Corporation, Lawrence Merchandising Corporation	96–2851	09/10/96
	96–2862	09/10/96
American Securities Partners, L.P., CRI Holding, Inc., CRI Holdings, Inc.  Archer-Daniels-Mildland Company, Roberto Gonzalez Barrera, Gruma S.A. de C.V	96-2662	
		09/11/96
Benedictine Health System, Duluth Clinic, Ltd., Duluth Clinic, Ltd	96–2678	09/11/96
Duluth Clinic, Ltd., Benedictine Health System, Benedictine Health System	96–2679	09/11/96
Kellogg Company, James Appold, Consolidated Biscuit Company	96–2727	09/11/96
Astor Holdings, Inc., ADCO Technologies Inc., ADCO Technologies, Inc	96–2734	09/11/96
Integrated Health Services, Inc., Signature Home Care, Inc., Signature Home Care, Inc.	96–2765	09/11/96
Edward H. Hamm, The Roanoke Companies, Inc., The Roanoke Companies, Inc	96–2768	09/11/96
St. Ives Group plc, Richard Perlmuter, The Perlmuter Printing Company	96–2977	09/11/96
Jean-Pierre Savare, Kirk R. Hyde, Kirk Plastic Company, Inc	96–2810	09/11/96
Merrill Lynch & Co., Inc., Hotchkis and Wiley, a Delaware L.L.C., Hotchkis and Wiley, a Delaware L.L.C	96–2815	09/11/96
OSI Holdings Corp., Payco American Corporation, Payco American Corporation	96–2823	09/11/96
Paul G. Allen, Edward M. Snider, Ticketmaster Delaware Valley, Inc	96–2719	09/12/96
Liechtenstein Global Trust, AG, Chancellor Partners, L.P., Chancellor Capital Mangement, Inc	96–2792	09/12/96
Employers Insurance of Wausau, Nationwide Mutual Insurance Company, San Diego Lotus Corp	96–2788	09/13/96
St. Jude Medical, Inc., Cyberonics, Inc., Cyberonics, Inc.	96–2820	9/13/96
First Data Corporation, Old Kent Financial Corporation, Old Kent Bank	96–2844	9/13/96
Munchener Ruckversicherungs-Gesellschaft, American Re Associates, L.P., American Re Corporation	96-2859	9/13/96
Coca-Cola Enterprises, Inc., Ahmad Hbouss, Nora Beverages Inc	96-2860	9/13/96
Memtec Limited, Gelman Sciences, Inc., Gelman Sciences, Inc.	96-2864	9/13/96
Hicks, Muse, Tate & Furst Equity Fund III, L.P., Circo Craft Co. Inc., Circo Craft Co. Inc.	96-2867	9/13/96
Richfood Holdings, Inc., Charles J. Greco, Norristown Wholesale, Inc	96-2874	9/13/96
Masayoshi Son, Concentric Network Corporation, Concentric Network Corporation	96-2880	9/13/96
Randgold & Exploration Company Limited, The Broken Hill Proprietary Company Ltd., BHP Minerals Mali Inc	96-2881	9/13/96
Komatsu Ltd., Robert G. Thomson, Rocky Mountain Machinery Company	96-2887	9/13/96
Franklin Electronic Publishers, Incorporated, Water Street Corporate Recovery Fund I, L.P., Insilco Corporation	96–2908	9/13/96

#### FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Renee A. Horton Contact Representatives

Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, DC 20580, (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 96–24709 Filed 9–25–96; 8:45 am] BILLING CODE 6750–01–M

# GENERAL SERVICES ADMINISTRATION

Office of Policy and Evaluation; Notice of Reporting Requirement Under Executive Order 12999—Educational Technology: Ensuring Opportunity for All Children In the Next Century

## Summary

Executive Order 12999 was signed by President Clinton on April 17, 1996. The order streamlines the transfer of excess educationally useful equipment, including Federal computer equipment, to schools and nonprofit organizations pursuant to section 11(i) of the Stevenson Wydler Technology Innovation Act, as amended (15 U.S.C. 3710(i)). The Stevenson-Wydler Act

authorizes the heads of Federal agencies and laboratories to transfer excess research equipment directly to educational institutions or nonprofit organizations for technical and scientific education and research.

The order mandates that agencies give the highest preference permitted by law to elementary and secondary schools. It further directs agencies to report to GSA, any excess research equipment that is transferred directly to schools.

In addition to the reporting requirement in EO 12999, section 202(e) of the Federal Property and Administrative Services Act of 1949, as amended (40 U.S.C. 483(e)), requires executive agencies to submit to GSA an annual report of personal property furnished to non-Federal recipients

(Non-Federal Recipients Report) during the previous fiscal year.

In an effort to minimize agencies' reporting burden, GSA has identified an already existing reporting vehicle (i.e., the Non-Federal Recipients Report) to satisfy the reporting requirement of EO 12999. Agencies must, therefore, be sure to include any transfers under EO 12999 in the Non-Federal Recipients Report. The report, in letter form, must include the name and address of each recipient, the original acquisition cost of all property furnished to each recipient identified by the appropriate two-digit Federal supply classification group, and an explanation as to the type of recipient; e.g., schools that receive property under EO 12999, other Stevension-Wydler Act donees, all contractors (fixed-price, costreimbursable, etc.), all grantees (project, formula, etc.), and any other individual or organization that is not a Federal agency. The report is required to be submitted to GSA within 90 calendar days after the close of each fiscal year. Negative reports are required.

Additional information may be obtained by writing to the General Services Administration, Office of Governmentwide Policy, Personal Property Management Policy Division (MTP), Washington, DC 20405.

Dated: September 12, 1996.

G. Martin Wagner, Associate Administrator.

[FR Doc. 96-24680 Filed 9-25-96; 8:45 am]

BILLING CODE 6820-34-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices: Announcement of Meeting and Request for Comments on Proposed Incorporation of IPV/OPV Sequential Schedule Into the Vaccines for Children Program

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Advisory Committee on Immunization Practices (ACIP).

Times and Dates:
8:30 a.m.-6:00 p.m., October 23, 1996
8:30 a.m.-1:15 p.m., October 24, 1996
Place: CDC, Auditorium A, Building 2,
1600 Clifton Road, NE, Atlanta, Georgia
30333.

*Status:* Open to the public, limited only by the space available.

#### Purpose

The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. § 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise, the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) Program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

#### Matters to be Discussed

Under the authority of 42 U.S.C. § 1396s, the Committee will consider adoption of a resolution to incorporate into the VFC Program a recommended sequential schedule of inactivated poliovirus vaccine (IPV) followed by oral poliovirus vaccine (OPV), with schedules of OPV alone or IPV alone also being acceptable. This proposed VFC resolution is consistent with the Committee's general poliomyelitis recommendation that was adopted at the June 20, 1996, ACIP meeting.

Given the considerable interest in the polio immunization schedule, opportunity for submitting written comments was provided and a public hearing was held prior to the Committee's adoption of their general poliomyelitis recommendation at the June 20 ACIP meeting. The Committee now invites submission of written comments on the proposed VFC resolution pertaining to incorporation of the sequential IPV/OPV schedule into the VFC Program. Copies of the proposed resolution are available by notifying the contact person. Copies will be sent electronically upon request. Written comments on the proposed resolution should be submitted to the contact person and must be received by October 18, 1996.

Other topics to be discussed at the meeting include a draft statement on measles, mumps, and rubella (MMR); implementation of polio vaccination recommendation; acellular pertussis vaccines recommendations; recommendations for rabies postexposure prophylaxis (PEP); COMVAX® (combined Hib and Hepatitis B vaccine); draft statement on the immunization of health care workers; varicella vaccine update; recommendations for strategies to increase immunization coverage; the National Immunization Survey (NIS); assessment and feedback of practicebased immunization coverage data; activation of HIV replication due to immunizations and acute illnesses; harmonization of the childhood immunization schedule; status of SmithKline Beecham Biological's candidate herpes simplex virus vaccine; update on Vaccine Injury Compensation Program; and the results of a study on influenza during pregnancy. Other matters of relevance among the Committee's objectives may be discussed.

Agenda items are subject to change as priorities dictate.

# CONTACT PERSON FOR MORE INFORMATION: Gloria A. Kovach, Committee Management Specialist, CDC (16–4346), 1600 Clifton Road, NE, Mailstop D50, Atlanta, Georgia 30333, telephone 404/639–7250.

Dated: September 23, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–244797 Filed 9–25–96; 8:45 am] BILLING CODE 4163–18–M

#### Advisory Committee for Injury Prevention and Control (ACIPC): Family and Intimate Violence Prevention Subcommittee: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee meeting.

*Name:* ACIPC Family and Intimate Violence Prevention Subcommittee.

Time and Date: 8:30 a.m.-4 p.m., October 21, 1996.

*Place:* Terrace Garden Hotel Buckhead, 3405 Lenox Road, NE, Atlanta, Georgia 30326.

*Status:* Open to the public, limited only by the space available.

Purpose: To provide and make recommendations to ACIPC and the Director, National Center for Injury Prevention and Control (NCIPC), regarding feasible goals for prevention and control of family and intimate violence. The Subcommittee makes recommendations regarding policies, strategies, objectives and priorities; and advises on the development of a national plan for family and intimate violence and the development of new technologies and their subsequent application.

#### Matters to be Discussed

The Subcommittee will discuss ways the CDC can implement the recommendations proposed in the National Research Council Report, Understanding Violence Against Women.